-+ 0.00%
-+ 0.00%
-+ 0.00%

ROYALTY PHARMA ACQUIRES ROYALTY INTEREST IN NUVALENT’S NELADALKIB AND ZIDESAMTINIB FOR UP TO $315 MILLION

路透·12/16/2025 12:15:00

登录查看新闻详情